troxacitabine has been researched along with idarubicin in 4 studies
| Studies (troxacitabine) | Trials (troxacitabine) | Recent Studies (post-2010) (troxacitabine) | Studies (idarubicin) | Trials (idarubicin) | Recent Studies (post-2010) (idarubicin) |
|---|---|---|---|---|---|
| 72 | 17 | 2 | 1,795 | 454 | 487 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Giles, FJ | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Berry, DA; Cortes, JE; Estey, EH; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Thomas, DA; Verstovsek, S; Wathen, JK; Xiao, LC | 1 |
1 review(s) available for troxacitabine and idarubicin
| Article | Year |
|---|---|
Troxacitabine-based therapy of refractory leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Cytosine; Dioxolanes; Humans; Idarubicin; Leukemia; Remission Induction; Topotecan | 2002 |
2 trial(s) available for troxacitabine and idarubicin
| Article | Year |
|---|---|
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytosine; Dioxolanes; Female; Humans; Idarubicin; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival; Treatment Outcome | 2003 |
1 other study(ies) available for troxacitabine and idarubicin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |